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Preventive Trichuris suis ova 
(TSO) treatment protects 
immunocompetent rabbits 
from DSS colitis but may be 
detrimental under conditions of 
immunosuppression
Irina Leonardi1,5, Alexandra Gerstgrasser1, Thomas S. B. Schmidt  2, Flora Nicholls3, 
Bernhard Tewes4, Roland Greinwald4, Christian von Mering  2, Gerhard Rogler1 & Isabelle 
Frey-Wagner  1
Trichuris suis ova (TSO) have been tested for therapeutic application in inflammatory bowel diseases 
(IBD) yet understanding of the underlying mechanisms and safety in an immunocompromised host is 
limited due to lack of a suitable animal model. We used a recently established rabbit model of dextran 
sodium sulphate (DSS) induced colitis to study the efficacy, mechanisms and safety of TSO therapy in 
immunocompetent and immunosuppressed animals. TSO treatment prevented the DSS induced weight 
loss, delayed the onset of DSS induced symptoms by 2 days and significantly reduced the disease 
activity (DAI). TSO treatment protected caecal histology and prevented the colitis-associated loss in 
faecal microbiota diversity. Mainly the transcriptome of lamina propria mononuclear cells (LPMC) was 
affected by TSO treatment, showing dampened innate and adaptive inflammatory responses. The 
protective effect of TSO was lost in immunosuppressed rabbits, where TSO exacerbated colitis. Our 
data show that preventive TSO treatment ameliorates colitis severity in immunocompetent rabbits, 
modulates LPMC immune responses and reduces faecal dysbiosis. In contrast, the same TSO treatment 
exacerbates colitis in immunosuppressed animals. Our data provide further evidence for a therapeutic 
effect of TSO in IBD, yet caution is required with regard to TSO treatment in immunosuppressed 
patients.
The aetiology of inflammatory bowel disease (IBD) is complex and not fully understood, yet. Nonetheless, the 
increasing incidence in developing nations suggests that the environment plays a critical role in the pathogenesis 
of both ulcerative colitis (UC) and Crohn’s disease (CD)1. Among various factors, a clear inverse correlation 
exists between the prevalence of IBD and soil-transmitted helminthic infections2. According to the old-friends 
hypothesis, helminths are intestinal symbionts that co-evolved with the adaptive immune system and are thereby 
essential for its proper maturation and functioning3.
Immune-modulation exerted by helminths has been proposed for the prevention and treatment of various 
immune-related diseases4. Different nematode species have been shown to suppress inflammation in mouse mod-
els of experimental colitis, mainly through the action of their excretory secretory (ES) products5. ES products 
of Ancylostoma species reduced Th1 and Th17 responses and ameliorated inflammation in models of chemi-
cally induced colitis6–8. Acanthocheilonema vitae secreted a Cystatin that reduced inflammatory macrophages 
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in the colon and the local production of inflammatory cytokines while increasing the numbers of regulatory T 
cells (Tregs) in dextran sodium sulphate (DSS) colitis9. ES produced by Nippostrongylus brasiliensis directly sup-
pressed IL-12p40 production by DCs10. Heligmosomoides polygyrus caused the expansion of tolerogenic DCs that 
blocked antigen-specific IFNγ and IL-17 T cell responses and attenuated colitis11,12. Mice previously infected with 
Trichuris muris recovered faster from DSS colitis and showed an increased regeneration of the mucosa suggesting 
that the protective effect of intestinal nematodes can persist after their clearance from the intestine13.
Besides their immunomodulatory role, intestinal nematodes might positively affect the dysbiosis observed 
during intestinal inflammation. The microbiota of IBD patients is characterized by decreased diversity, 
reduced abundance of Firmicutes (CD) or Bacteroidetes (UC) and increased abundance of Proteobacteria and/
or Actinobacteria14. H. polygyrus has been shown to increase the abundance of Lactobacillaceae in the ileum 
of infected mice15,16. Similarly, the swine parasite Trichuris suis affected the abundance of Proteobacteria and 
Deferribacteres in the pig colon17. Whether the modulation of the gut microbiota also contributes to the thera-
peutic effect of helminths in intestinal inflammation has not been studied so far.
T. suis is the main helminth species tested in human subjects. Trials in human patients have been performed 
by administration of different doses of embryonated T. suis ova (TSO)18. The current view is that T. suis larvae 
hatch and transiently colonize the human intestine for some weeks without reaching sexual maturity19.
A recent Cochrane systematic review came to the conclusion that the evidence in support of the efficacy and 
safety of TSO for the treatment of IBD remains inconclusive20. The initial open-label studies showed promising 
clinical efficacy and safety21. Yet, larger multicentre studies failed to show a significant effect of TSO in compari-
son to placebo in mild to moderate IBD patients22.
The safety of helminth therapy in immunosuppressed individuals, that constitute the majority of IBD patients, 
is a major concern. Although the initial studies did not report severe adverse effects among the immunosup-
pressed patients receiving TSO23, Kradin et al. reported the case of an invasive iatrogenic infection in an immu-
nosuppressed CD patient24. Of note, the nature of IBD itself might mask the presence of TSO induced symptoms, 
thereby complicating the assessment of the side effects of TSO.
To date, the lack of a suitable animal model has hampered detailed investigations into the mechanisms and 
safety of TSO treatment for IBD. Since the course of a T. suis infection in the rabbit intestine is similar to the 
transient colonisation proposed for humans, we recently developed a colitis model in rabbits by administration of 
DSS25. Here, we used this model to investigate the efficacy and safety of a preventive TSO therapy as proposed for 
IBD patients for maintenance of remission, in immunocompetent and immunosuppressed animals.
Results
TSO prevent colitis in immunocompetent rabbits. To investigate whether TSO can ameliorate the out-
come of colitis, we administered three doses of 2500 TSO prior to the administration of DSS (Fig. 1A). Following 
Figure 1. Preventive TSO treatment ameliorates DSS colitis. (A) NZW rabbits received 2500 TSO at day 1, 14 
and 21 (intra-gastrically). At day 26 colitis was induced by administration of 0.1% DSS in the daily beverage 
for 5 days. (B) Body weight is shown as percentage of individual weight at start of DSS colitis induction (day 
26). (C) Clinical symptoms (reduction in food and beverage intake, fur cleanliness, weight loss and stool 
consistency), were scored daily and summarized as disease activity index (DAI). Bars show mean ± SEM, 
*P < 0.05, **P < 0.01, ***P < 0.001, two-sided p-Value, Mann-Whitney test relative to the vehicle DSS group 
(#) and to the vehicle water group (*). Data are pooled from two independent experiments with n = 3–4 rabbits 
per group.
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DSS administration, vehicle treated rabbits (Veh) rabbits exhibited watery diarrhea and significant weight loss in 
comparison to the control starting on day five of DSS administration and continuing until the end of the exper-
iment. In contrast, TSO treated animals maintained the constant weight gain observed in age-matched healthy 
controls (Fig. 1B, Supplementary Figure 1) thus that there was a significant difference in weight change between 
the TSO DSS and the DSS group on day 9 and 10 after start of DSS administration. Concurrent to weight loss, Veh 
animals developed severe symptoms. At day 9 after the start of DSS administration, they had reached an average 
disease activity index (DAI, Fig. 1B) of 1.6 ± 0.8. In contrast, TSO treatment delayed the onset of symptoms and 
reduced the disease severity significantly (DAI at day 9: 0.7 ± 0.2, P < 0.05 in comparison to the Veh-DSS group). 
Importantly, TSO treatment alone did not induce any weight loss and no symptoms were observed in healthy 
animals (Fig. 1B and C).
TSO prevent severe histopathology in the caecal mucosa. We next examined the effect of TSO on 
the DSS induced caecum inflammation. Histologically, the caecum of TSO treated healthy rabbits did not show 
any sign of epithelial damage or villous stunting yet some changes in crypt architecture were visible (Fig. 2A). As 
expected, TSO induced a strong infiltration of eosinophils into the lamina propria even in the absence of DSS 
administration (Fig. 2B), leading to a significantly increased peroxidase activity (Fig. 3A). In Veh animals, DSS 
triggered a caecal pathology characterized by profound morphological changes and a marked infiltration of lym-
phocytes into the lamina propria and into the epithelium (Fig. 2C,D and E). TSO partially protected the caecal 
Figure 2. TSO treatment reduces the caecum histopathology of DSS colitis. Caecal samples were collected 
after euthanasia at day 35. (A) HE stained caecum sections from vehicle or TSO treated rabbits with or without 
colitis induction. Bars = 100 µm. (B) Inflammatory cell infiltrate score based on the lymphocyte infiltrate into 
the lamina propria and epithelium (2–8). (C) Intestinal architecture score based on independent scoring of 
villous stunting, epithelium damage and crypt distortion (3–12). (D) Inflammatory cell infiltrate and intestinal 
architecture score were summarized to a combined histology score (5–20). (E) Quantification of the average 
number of eosinophils within a 40 x field of caecum. Data are pooled from two independent experiments 
with n = 3–5 animals per group. For the scoring, three caecal samples per rabbit were collected and evaluated 
separately for at least three rabbits per group. *P < 0.1, **P < 0.05, two-sided p-Value, Mann-Whitney 
test relative to vehicle water control (*) or to vehicle DSS (#). Dots represent single animals, bars represent 
mean ± SEM.
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mucosa from the DSS-induced morphological changes and reduced lymphocyte infiltration into the mucosa 
(Fig. 2A). Blinded semi-quantitative scoring of morphological and inflammatory histological parameters showed 
that TSO prevented the development of histological damage in half of the treated animals (Fig. 2C,D and E). 
This observation, suggests the existence of individual-specific factors that might modulate the efficacy of TSO 
treatment. Innate leukocyte invasion was assessed by measurement of the peroxidase activity. The overall perox-
idase activity was increased in the TSO treated animals even in the absence of DSS induced injury (Fig. 3A). This 
increase was due to a TSO induced infiltration of eosinophils as treatment with the eosinophils’ peroxidase (EPO) 
inhibitor aminotriazole (AMT) reduced the peroxidase activity in the TSO treated animals and revealed a trend 
towards decreased neutrophil infiltration in the TSO DSS animals (Fig. 3B).
TSO influence the faecal and caecal microbiota. The immune-effect of intestinal helminths has been 
linked to the modulation of intestinal microbiota16 Since T. suis resides in close contact with caecal commensal 
bacteria, we hypothesized that TSO administration might be associated with distinct changes in the bacterial 
community in the caecum and, as a consequence, in the faeces. We therefore assessed how T. suis influences the 
microbial community in healthy and colitic rabbits.
In faeces, DSS treatment caused a statistically significant decrease in both richness (P < 0.05, Abundance-based 
Coverage Estimator, ACE) and Shannon diversity26,27. This loss of richness and diversity was significantly reduced 
by pre-treatment with TSO (Fig. 4A,B).
We next compared the groups in terms of community composition in a Principal Coordinate Analysis (PCoA) 
based on Bray-Curtis dissimilarities. Permutation multivariate ANOVA (PERMANOVA) analysis revealed a sig-
nificant effect of DSS on both caecal and faecal communities (P < 0.05, Fig. 4C,D). Although global analysis 
did not reveal clear clustering by TSO treatment, the abundance of several bacterial taxa showed significant 
variation between the groups. In faeces, TSO prevented the DSS-induced increase in members of the phy-
lum Bacteroidetes and the decrease in Firmicutes. In the caecum, similar trends, although not significant, were 
observed (Supplementary Figure 2). To identify colitis-associated bacteria and investigate how TSO influenced 
their abundance, EdgeR was used to identify the differentially abundant OTUs with respect to the untreated 
control group (Fig. 5). Following DSS, Bacteroidetes dorei, Desulfovibrionaceae sp, Eubacterium sp, Spiroplasma 
sp and Clostridium sp abundances increased significantly relative to water-treated controls (FDR < 0.01). Further, 
the relative abundances of these OTUs in both caecum and faeces correlated strongly with different indicators 
of colitis severity (weight change, disease activity and histology score). In contrast, the frequency of several 
Ruminococcaceae sp. OTUs and other Clostridiales decreased upon DSS and had a strong negative correlation 
with colitis severity. Further, TSO prevented the colitis-associated peak of B. dorei and Desulfovibrionaceae sp. in 
the caecum.
TSO modulate the IEC and LPMC transcriptome. To gain further insights into the mechanisms of TSO 
treatment, we performed genome wide expression analysis on intestinal epithelial cells (IEC) and lamina propria 
mononuclear cells (LPMC) isolated from caecum samples by RNA sequencing (RNAseq). Hierarchical clustering 
Figure 3. Neutrophil and eosinophil infiltration into the caecum. Infiltration was determined indirectly by 
measuring the caecal peroxidase activity. Caecal specimens were excised and homogenized. The supernatants 
were assayed for the determination of peroxidase activity with (B) or without (A) the selective eosinophil-
peroxidase inhibitor aminotriazole (AMT). Activity was normalized to the total protein content as determined 
by BCA test. Dots represent single animals, n = 3–5 animals per group, bars show mean ± SEM, *P < 0.05, 
unpaired t test.
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(Supplementary Figure 3) revealed distinct expression profiles for EC and LPMC and highlighted a strong effect 
of TSO treatment particularly in LPMC, whereas the effect in EC was milder.
In LPMC, we identified 511 differentially expressed genes (log2 fold change |FC| > 1, FDR corrected 
p-Value < 0.05) in the TSO DSS animals in comparison to the Veh Control group. 423 genes were expressed at 
lower level and 88 were up-regulated in the TSO DSS animals (Fig. 6).
Genes with significantly altered mRNA levels were analysed by MetaCore to determine the biological rele-
vance of their differential expression. Enrichment analysis showed that in the healthy mucosa, TSO influenced the 
expression of genes known to be associated with parasitic infections such as TCR signalling, phagocytosis, innate 
inflammatory response and macrophage migration inhibitory factor (MIF) signalling. Interestingly, 42% of the 
genes over-expressed in response to TSO in IEC and LPMC have been shown to be over-expressed in the caecum 
of T. muris infected mice28 (Supplementary Figure 4 and Supplementary Table 1). In the LPMC of DSS treated 
animals, TSO treatment led to the down-regulation of genes involved in cell-adhesion (Fig. 6A) and limited the 
expression of genes involved in innate inflammation and Th17 pathways (Fig. 6B). Differential expression of 
selected transcripts was verified by rt-qPCR and revealed a similar fold change as obtained by mRNA sequencing 
(Fig. 6C,D).
TSO exacerbate colitis in immunosuppressed animals. Since most IBD patients are on immuno-
suppressive therapy we investigated how TSO treatment affects DSS colitis in immunosuppressed (IS) rab-
bits (Supplementary Figure 5A). Cyclosporine and Methylprednisolone are used in IBD to treat severe acute 
UC either as monotherapy or in combination. The efficiency of immunosuppression by Cyclosporine and 
Methylprednisolone was confirmed by differential blood count (Supplementary Figure 5C). Of note, a reduced 
weight gain was observed in IS animals independently of TSO treatment (Supplementary Figure 5B). After 2 
weeks of IS treatment leukocyte count fell below 5.109 cells/µl, with lymphocytes being the most affected cell 
Figure 4. TSO partially prevents the DSS induced shift in gut microbiota composition. Microbiota richness 
in caecum (A) and faeces (B) as assessed by abundance based coverage estimator, (ACE). PCoA ordination 
based on Bray-Curtis dissimilarities show shifts in community composition for caecal (C) and faecal samples 
(D) in response to DSS treatment in immunocompetent animals. The percentage of variation explained 
is given in parentheses, Increasing distance in two-dimensional space represents increasingly dissimilar 
communities.*P < 0.05, one-sided p-Value, Mann-Whitney test relative to vehicle water control. Dots represent 
single animals n = 7–8 animals per group, bars represent mean ± SEM.
www.nature.com/scientificreports/
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population. In IS animals, TSO did not induce any clinical symptom and no adverse effects were observed in the 
absence of colitis. In contrast, colitis induction was followed by severe weight loss in the TSO treated IS rabbits 
(Fig. 7A). Further, TSO exacerbated the DSS induced symptoms that three out of nine IS animals had to be euth-
anized prior to the scheduled end of the experiment.
Histological examination (Fig. 7B), showed increased villous stunting and altered crypt architecture in IS 
TSO DSS animals as well as enhanced infiltration of lymphocytes into the epithelial layer. The extent of immune 
cell infiltration and morphological alteration were elevated in comparison to the IS DSS control group (Fig. 7C). 
Further examination revealed the presence of TSO larvae in the caecal mucosa of 5 out of 9 IS TSO DSS rab-
bits. Parasite size and morphological features were characteristic of a late larval or early adult stage, with distin-
guishable tripartite oesophagus and well-developed reproductive organs (Fig. 7D). No un-embryonated eggs 
were detected by faecal sedimentation-flotation, suggesting that T. suis had not reached sexual maturity (data 
not shown). Larvae were not observed in other parts of the intestine (ileum, proximal and distal colon). Yet, 
PCR-detection revealed the presence of T. suis in the colon of 4 out of 10 IS TSO DSS and 2 out of 2 IS TSO Water 
rabbits (Fig. 7E). The spread of T. suis outside the caecal niche confirms that IS rabbits fail to control the helminth 
infection. Analysis of the peroxidase activity in IS animals, only, showed a small increase after TSO treatment for 
both the global peroxidase activity and the MPO specific activity (Supplementary Figure 6). This was in accord-
ance with the absence of a significant increase in eosinophilic infiltrate observed by histology (data not shown).
Figure 5. Association of individual OTUs with treatment and colitis severity. Differential OTU abundance in 
the caecal microbiota between treatment and baseline conditions were assessed using the R package edgeR. The 
top 100 OTUs showing the most significant abundance shifts (FDR < 0.01) in at least one tested condition or 
a strong correlation to at least one parameter of colitis severity (Spearman correlation, rho <|0.5|) are shown. 
The leftmost columns indicate global OTU size (relative abundance in the entire dataset) in shades of grey and 
order-level OTU taxonomy in pastel colours (white indicates unknown taxonomy at order level). Blue/red heat 
maps on the left indicate the fold change (log2|FC|) of OTU abundances between the test conditions; pink/green 
heat maps on the right indicate correlation strength to colitis severity parameters. OTUs were clustered on the 
y-axis based on Pearson distances of their fold changes across conditions.
www.nature.com/scientificreports/
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Immunosuppression increases the frequency of colitis-associated bacteria. We next assessed 
whether the abrogation of the protective effect of TSO observed in IS rabbits was accompanied by shifts in the 
intestinal bacterial community. In IS rabbits, TSO treatment did not affect the community evenness, richness and 
between-sample β-diversity as assessed by Bray-Curtis-dissimilarity (Fig. 8A and B).
At OTU level, several strains associated with a more severe colitis severity were decreased in the DSS IS ani-
mals in comparison to immunocompetent animals, which correlates with the observed amelioration of colitis 
severity (Fig. 5). In contrast, concomitant IS and TSO treatment caused an increase of colitis associated OTUs. 
In particular, TSO led to an increased frequency of B. dorei, Desulfovibrionaceae sp and Eubacterium sp OTUs in 
immunosuppressed animals.
Figure 6. Differential mRNA expression in LPMC. Genome wide expression analysis by RNAseq was 
performed with RNA from LPMCs isolated from rabbit caeca (n = three per group). Expression profiles of 
the different treatment groups were sorted by hierarchical clustering. Left) Number of under- (A) and over-
expressed (B) mRNAs in the TSO DSS, Veh DSS and TSO Water groups in comparison to the control Veh 
Water group. Transcripts having a log2FC > |1| and P < 0.05 were considered as differentially expressed and 
included in further analyses. Right) Significantly affected Process Networks (PN) as identified by MetaCore™. 
PN without relevance to the investigated tissue and model were omitted. Numbers in parentheses provide the 
PN rank. (C) Validation of differential mRNA expression of COX-2, IL-6, and MMP-1 in LPMC (data pooled 
from two separate experiments, with n = 3–4 per group) by rt-qPCR. Expression was calculated with the ΔΔCt 
method relative to GAPDH and gave similar results as RNAseq (D). *P < 0.05, two-sided p-Value, Mann-
Whitney test relative to vehicle water control if not indicated otherwise. Dots represent single animals, bars 
represent mean ± SEM.
www.nature.com/scientificreports/
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Figure 7. Immunosuppression abrogates the protective effects of TSO and exacerbates the DSS induced 
damage and inflammation of the caecal mucosa. (A) Body weight change relative to the baseline at DSS colitis 
induction (day 26). (B) Representative HE stained specimens of caecal mucosa (day 35). IS: immunosuppressed 
rabbits, control: immunocompetent rabbits. Bars = 100 µm. 3 specimens per rabbit were assessed. Filled 
arrowhead: T. suis schistosome. (C) Inflammatory cell infiltrate score based on the lymphocyte infiltrate into 
the lamina propria and epithelium (2–8). Intestinal architecture score based on independent scoring of villous 
stunting, epithelium damage and crypt distortion (3–12). Inflammatory cell infiltrate and intestinal architecture 
score were summarized to a combined histology score (5–20). (D) HE stained section of the caecal mucosa of 
IS TSO-DSS rabbits showing the presence of adult T. suis. Left panel: longitudinal section of the posterior part; 
Right panel: cross section of the posterior end of the parasite. S: stychosome nucleus; Bb: bacillary band; C: 
cuticle; O: reproductive organs; D: digestive tract; M: muscle layer. Bars = 20 µm. Empty arrowhead: syncytial 
tunnel derived from the host’s caecal epithelium. (E) Percentage of animals tested positive for Trichuris by PCR 
in different regions of the gastrointestinal tract (caecum, colon and ileum). W: water, D: DSS, V: Vehicle, T: 
www.nature.com/scientificreports/
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TSO decreases the expression of alternative macrophage activation markers in immuno-
suppressed rabbits. Analysis of immune response markers in LPMC showed that immunosuppression 
reduced the increase in markers of alternative macrophage activation ARG-1 and ALOX-15 (Fig. 9). Similarly, 
the increase in expression of SLC15A2 was abrogated, whereas mRNA levels of IL-6 increased in IS TSO DSS 
animals, although not significantly. On the other hand, the reduction in TNFα mRNA levels observed in the 
immunocompetent rabbits persisted.
Discussion
The chronic course of inflammatory bowel disease requires a long-term treatment that maximizes the 
anti-inflammatory action while minimizing the systemic effects. Unfortunately, currently available therapies have 
limitations in both efficacy and/or tolerability. The first human trials investigating a therapeutic effect of Trichuris 
suis in UC and CD patients were promising23,29. Yet, larger multicentre studies could not show a significant effect 
of T. suis ova (TSO) in comparison to placebo in mild to moderate IBD patients. Currently, the available evidence 
in support of TSO therapy is judged insufficient20. Furthermore, the mechanisms underlying TSO therapy at 
molecular level as well as the safety in immunosuppressed individuals could not be investigated so far due to the 
lack of a suitable animal model.
Since T. suis shows a similar transient colonization in both humans and rabbits, we chose to study the efficacy 
and safety of TSO in a recently developed rabbit model of colitis25.
Consistent with human studies, we found that a preventive treatment with three doses of 2500 TSO protected 
from colitis-induced weight loss, reduced the disease activity index and limited the caecal pathology.
Intriguingly, whole genome transcriptome analysis of caecal LPMC and IEC samples showed a strong effect 
of TSO treatment on LPMC gene expression, whereas the effect on IEC was milder. This observation agrees with 
evidence that T. suis excreted or secreted (ES) compounds (such as glycans) increase epithelial permeability, 
and allows the passage of immunomodulatory soluble compounds to the lamina propria30,31. Supporting these 
findings, we found that several mRNAs involved in the degradation of connective tissues were over-expressed 
in caecal IEC upon TSO treatment. T. suis ES products have been linked to chemokine, T-cell receptor and 
TGFβ signalling as well as leukocyte trans endothelial migration31. Accordingly, we observed a TSO-induced 
decrease in expression of mRNAs involved in cell-adhesion, endothelium-leukocytes interactions and chemot-
axis. Furthermore, TSO also limited the DSS-induced increase in expression of mRNAs involved in Th17 immune 
response and were associated with an increase in expression of mRNAs involved in innate inflammation, IL-4 
and histamine signalling. Whilst these observations largely accord with the typical anti-helminth response, a 
species-specific response to T. suis might occur, especially given the profound differences observed when compar-
ing its transcriptome with those of other well studied helminths32. Our data suggest that TSO treatment predom-
inantly affects LP immune cells. Since the majority of IBD patients receive an immunosuppressive therapy33, the 
protective modulation of the immune response could be lost, thus rendering the therapy ineffective. Furthermore, 
although T. suis is not a human parasite, an aberrant migration of Trichuris particularly in an immunosuppressed 
host with impaired gut barrier function cannot be excluded a priori. In humans, trichuriasis symptoms can range 
from mild digestive tract distress to anaemia, dysentery, bleeding, abdominal pain and more generalized effects, 
such as nausea, vomiting, anaemia and peripheral blood eosinophilia34.
Although no side-effects were reported in the published clinical trials in IBD18,23,29,35, the disease symptoms 
might mask the consequences of a Trichuris induced intestinal inflammation. In fact, symptoms have been 
observed in studies testing a TSO therapy for non-gastrointestinal diseases. In a randomized double-blinded 
placebo-controlled clinical trial in allergic rhinitis, patients ingesting TSO had a 3 to 19-fold higher rate of gastro-
intestinal episodes (flatulence, diarrhoea and abdominal pain) compared with placebo subjects36,37. Similarly, in 
two small pilot studies in multiple sclerosis, patients experienced mild transient symptoms at about 30 days after 
the first TSO dose38,39.
To address the lack of systematic studies of TSO in immunosuppressed individuals we tested the outcome of 
TSO administration in immunosuppressed rabbits. To achieve immunosuppression, we used a combination of 
cyclosporine and methylprednisolone. Cyclosporine acts rapidly and is effective in the management of severe UC, 
whereas corticosteroids are used for moderate to severe relapses of both IBD forms40.
Importantly, we show that in immunosuppressed rabbits, TSO exacerbated colitis and increased the mortal-
ity of the affected animals. Our results highlight the dangers of helminth therapy in immunosuppressed hosts. 
Histology revealed the presence of late-stage larvae in the caecum, suggesting a failure of the anti-helminth 
response when the intestinal barrier function is damaged and the immune response impaired. Our histological 
findings resemble those observed in an immunosuppressed CD patient that developed an iatrogenic Trichuris 
infection after treatment with TSO24.
Since Trichuris species are known to modulate the intestinal microbiota41,42 we investigated whether TSO 
treatment would modulate the bacterial communities and whether these changes could be associated with the 
observed protective effect. Analysis of microbiota revealed clear differences in the composition of the caecal and 
faecal microbiota of DSS treated rabbits in comparison to water treated controls.
TSO, Ctrl: Control, IS: immunosuppressed. Dots represent single animals, bars represent mean ± SEM, data 
were pooled from three independent experiments, n = 2–4 animals per group. *P < 0.05, **P < .01, two-sided 
p-Value, Mann-Whitney test between IS Veh DSS (n = 8‡) and IS TSO DSS (n = 9‡). ‡Number of animals at 
the start of the experiment. 3 IS TSO DSS and 1 IS Veh DSS animals reached the euthanasia criteria and were 
sacrificed at the indicated time point (†).
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As is commonly observed in IBD patients in comparison to healthy controls, the faecal microbiota of 
DSS-treated animals showed a significant reduction in community richness43. Importantly, TSO prevented this 
DSS-induced reduction, although– in contrast to previous reports from Trichuris infected individuals44 – healthy 
TSO-infected rabbits had a slight, albeit not significant, reduction in diversity. Our results confirm the trend 
observed in colitic Macaques after therapeutic treatment with T. trichiura42.
Our analysis identified several OTUs whose abundance in the rabbit microbiome correlated strongly with 
different indicators of colitis severity. The caecal microbiota of DSS treated rabbits prominently included 
Spiroplasma, Eubacterium and Clostridium OTUs as well as members of the Bacteroidetes phylum, in particular 
B. dorei. Increased abundance of B. dorei and other Bacteroides species has been implicated in inflammation in 
several immune-related diseases including UC, celiac disease and collagenous colitis45–47. TSO treatment signif-
icantly reduced the abundance of these taxa, comparable to the effect recently described for Heligmosoides poly-
gyrus infection in mice48. TSO also prevented the increase of OTUs belonging to the family Desulfovibrionaceae 
that have been implicated in UC pathogenesis via the production of hydrogen sulphide, which might exacerbate 
mucosal inflammation and ulceration49.
In both caecal and faecal samples, OTUs belonging to the Clostridium genus increased independently of 
TSO-treatment. Similarly, selected Clostridium species were strongly increased in treatment naive CD patients50. 
In contrast, other Clostridiales order belonging in particular to the genus Ruminococcus were strongly reduced in 
DSS-treated animals; a trend also observed in CD50 and UC51 patients.
To our knowledge, no study investigating the effect of immune suppression on the intestinal microbiota has 
been published. Interestingly, the DSS-induced reduction in alpha diversity was lost in immunosuppressed ani-
mals, suggesting that immune-suppression can mitigate colitis-associated dysbiosis. Immunosuppressed rabbits 
had a reduced frequency of OTUs positively associated with colitis markers and an increased frequency of several 
OTUs that had a negative correlation with colitis severity. This is in accordance with the anti-inflammatory effect 
exerted by the immunosuppressive treatment.
Figure 8. TSO do not affect gut microbiota composition in immunosuppressed animals. Microbiota richness 
in caecum (A) and faeces (B) as assessed by ACE. PCoA ordination based on Bray-Curtis dissimilarities show 
no shifts in community composition for caecal (C) and faecal samples (D) in immunosuppressed animals. 
The percentage of variation explained is given in parentheses; increasing distance in two-dimensional space 
represents increasingly dissimilar communities. Dots represent single animals, n = 4–8 animals per group. Bars 
represent mean ± SEM.
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Treatment with TSO abrogated the reduction of the majority of these colitis-associated species in the IS DSS 
group. At the same time, TSO prevented the increase of Clostridiales associated with reduced colitis severity, 
including members of Eubacteriaceae, Corynebacterium and Ruminococcaceae52. Recent studies showed that com-
mensal Clostridium bacteria promote anti-inflammatory immune responses by expanding and activating regula-
tory T cells53. A reduction of their protective regulatory stimuli might contribute to the exacerbated inflammation 
observed in the immunosuppressed TSO group. Whether the observed changes are causal to the increased colitis 
severity or rather, a consequence of the disturbed environment warrants further investigation.
In summary, our study provides further evidence for the therapeutic efficacy of a preventive TSO therapy 
in intestinal inflammation. Yet, immunosuppression interferes with TSO treatment, counteracts its therapeutic 
effect and might predispose towards adverse effects. Based on these findings, caution should be exercised when 
treating immunosuppressed IBD patients with TSO or other therapeutic parasites. Investigations into the thera-
peutic effect of parasite-derived products might allow exploiting the therapeutic potential of helminths without 
the risks associated with a therapeutic helminth infection.
Materials and Methods
Rabbits. All animal experiments were carried out according to Swiss animal welfare laws and approved by 
the veterinary office of Zurich (licenses No. 128-2010 and 231-3013). New Zealand white rabbits (Charles River, 
Kisslegg, Germany) weighing 1.9–2.1 kg (8–10 weeks of age) were maintained single-housed with water and 
food (standard rabbit maintenance diet – Provimi Kliba AG, Kaiseraugst, Switzerland, hay and straw) ad libitum 
on a 12:12 hour light/dark cycle. Upon arrival, animals were kept for at least 4 days under routine husbandry. 
Afterwards, drinking water was substituted by organic fennel tea (Hipp, Pfaffenhofen, Germany) ad libitum as 
fennel tea can mask the bitter taste of DSS that would reduce liquid intake in rabbits.
TSO administration. Rabbits were randomly assigned to treatment groups receiving either suspensions 
of 2500 TSO (embryonated T. suis eggs, supplied as ready-to-use inoculation doses) or the vehicle (Phosphoric 
acid buffer pH 5.0 with 0.05% potassium sorbate) in three oral doses at day 1, day 14 and day 21. Animals were 
fasted overnight prior to TSO administration and sedated with 0.4 ml Hypnorm (VetaPharma, Leeds, UK), s.c. 
The TSO suspension or vehicle (volume 15 ml) was completely filled in a syringe and administered to the animal 
using a gastric tube (i.e. Ruesch Katheter, CH14, REF 402101, Kernen, Germany). The animals were fed shortly 
after administration.
Colitis induction and clinical evaluation. DSS Colitis was induced at day 26 as described previously25. 
Rabbits received DSS (MP Biomedicals, Illkirch, France) dissolved in cold fennel tea at 0.1% w/v for 5 days. 
Control rabbits received cold fennel tea only. Animal weight, food and beverage intake, stool appearance and 
behaviour were monitored daily. A DAI was calculated according to Supplementary Table 2.
Figure 9. Effects of immunosuppression on the expression of different immune response markers in LPMC. 
LPMC where isolated from the caecal mucosa of control (ctrl) and immunosuppressed (IS) rabbits. Expression 
of selected mRNAs was determined by rt-qPCR relative to GAPDH as housekeeping gene. Bars represent 
Mean ± SEM from two pooled experiments. n = 2–4 animals per group. *P < 0.05, Mann-Whitney test.
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Immunosuppression. Immunosuppressive treatment was started 2 weeks prior to the first TSO gav-
age. The rabbits received cyclosporine (100 μl/kg/day, Sandimmun Neoral Trink Lösung 100 mg/ml; Novartis 
Pharma Schweiz AG, Basel, Switzerland) and methylprednisolone (1 mg/kg/day, 6α-Methylprednisolone 
21-hemisuccinate sodium salt -lyophilized powder, Sigma-Aldrich, Munich, Germany) for 2 weeks daily by oral 
administration. Afterwards, the dose was reduced to half and the treatment continued until the end of the exper-
iment. Control rabbits received vehicle (12% V/V EtOH). 5 ml of blood were collected from the marginal ear vein 
prior to immunosuppressive treatment and at day 1, 14, 21, and 35 and sent to the clinic of haematology (USZ, 
Zurich, Switzerland) for a complete blood count.
Euthanasia and Organ sampling. Euthanasia was performed on day 35 (unless described otherwise) with 
150 mg/kg Pentobarbital i.v. in deeply sedated animals (85 mg/kg ketamine hydrochloride, Vétoquinol, Bern, 
Switzerland and 4 mg/kg xylazine, Bayer, Lyssach, Switzerland).
The abdominal cavity was exposed by a midline laparotomy and samples were collected from the ileum, jeju-
num, duodenum, caecum and colon. For RNA extraction and myeloperoxidase activity analysis, the excised 
samples (0.5 cm in length) were opened by a longitudinal incision and rinsed with cold PBS. One cm2 sections of 
the caecum were extensively washed with cold PBS until complete removal of the luminal content. The samples 
were immediately snap-frozen in liquid nitrogen and stored at −80 °C until analysis. For histology, samples (three 
0.5 cm2 sections from different regions of the caecum or one 0.5 cm long section of other intestine segments) were 
collected. The samples were carefully washed and fixed with phosphate buffered 10% formalin solution. For RNA 
isolation, caecal samples (2 cm2) were extensively washed with cold PBS and stored on ice in 5% BSA in PBS until 
further processing.
Isolation of caecal LPMC and IEC. The dissected specimens were washed with Ca+- and Mg+-free PBS, 
the caecal fold was removed and discarded. The tissue was cut and incubated in medium containing 20 mM EDTA 
(Sigma-Aldrich) for 30 min at 37 °C on a shaking platform (150 rpm). IECs were detached by vortexing and pass-
ing through a 70 µm cell strainer (BD Biosciences, Erembodegem, Belgium). The IEC were washed twice, pelleted, 
resuspended in RLT buffer (Qiagen, Hilden, Germany), snap-frozen in liquid nitrogen and stored at −80 °C for 
later analysis. The remaining tissue containing LP with muscle layer was collected and incubated in one μg/ml 
collagenase type I CLS (Worthington Biochemical Corp., Freehold, New Jersey, USA) at 37 °C on a shaking plat-
form (300 rpm). After 15 minutes incubation, the suspension was vortexed and filtered through a 70 µl strainer. 
Cells were resuspended in 5% BSA in PBS. The undigested tissue was incubated with fresh collagenase solution 
for additional 15 minutes. The digestion was repeated three times and the washed LPMC were pooled and resus-
pended in DMEM with 5% FCS. LPMC were purified using Ficoll-Paque PLUS (GE Healthcare Europe GmbH, 
Freiburg Germany) gradient centrifugation for 40 min at 1200 rpm. The viability of the cells was confirmed by 
trypan blue staining. Cells were resuspended in RLT buffer (Qiagen, Hilden, Germany), snap-frozen in liquid 
nitrogen and stored at −80 °C for later analysis.
RNA isolation and genome wide mRNA expression analysis. Total RNA was isolated with the 
Qiacube system using the RNeasy Mini Kit with DNase digestion (Qiagen, Hilden, Germany) to eliminate 
genomic DNA. RNA integrity and quantity was determined on the Agilent 2100 Bioanalyzer (Agilent; Palo Alto, 
CA, USA). Samples with an integrity score ≥6.8 were sent to the Functional Genomics Centre Zurich (FGCZ) 
for sequencing.
Sequencing of the 2 × 250 bp inserts was performed on the Illumina HiSeq. 2500 v4 platform at the FGCZ. 
Fold change (FC) was used to express the changes in average gene expression between studied groups. FC was 
normalized against the control group. The following cut-offs were applied to identify differentially expressed 
genes: FDR-corrected-p-Value ≤ 0.05 and log2 (FC) ≥ |1.0|. The RNAseq data have been deposited in NCBI’s Gene 
Expression Omnibus and are accessible through GEO Series accession number GSE77372.
The ENSEMBL IDs were annotated using BetterBunny augmented annotation and analysis of rabbit genes 
(http://cptweb.cpt.wayne.edu)54. MetaCore™ (Thomson Reuters, http://portal.genego.com) was used to perform 
network analyses. Process networks (PN, groups of genes involved in main signalling and metabolic processes 
in the cell in the MetaCore™ database) were considered significant with a p-Value ≤ 0.05 and were listed on the 
basis of their relevance to IBD pathology.
Histopathological evaluation of colitis. After careful dissection and fixation, tissues were embedded in 
paraffin. Serial sections of five μm were cut using a microtome (Carl Zeiss AG, Feldbach, Switzerland) and stained 
with haematoxylin-eosin (HE). The histological changes in the caecum were quantified in a blinded manner by 
two investigators (range 1–24) for morphological features (villous stunting, villous epithelial injury and crypt 
distortion) and infiltration of immune cells (intraepithelial lymphocytes and infiltrating lymphocytes and plasma 
cells in the LP) as outlined in Supplementary Table 3.
RNA extraction and quantitative real-time PCR. Total RNA was isolated using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany) following the manufacturer’s recommendations. cDNA was synthesized with the 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Carlsbad, California, U.S.A). Gene expres-
sion was determined with a TaqMan® Gene Expression Assay (#Oc04097051_m1 IL-6; #Oc04250656_m1 MMP1; 
#Oc03398293_m1 PTGS2 (COX2); #Oc03398448_m1 SLC15A2; #Oc03397715_m1 TNFα; Oc03823548_s1 
ALOX-15A2; Oc03397217_m1 ARG-1; Applied Biosystems). Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) gene expression was measured as endogenous control (#Oc03823402_g1, Applied Biosystems) and 
used for calculation of relative mRNA expression by the ΔΔCt method. All samples were analysed in triplicate.
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Faecal and luminal microbiota analysis. Fresh faecal samples were collected at the start of the exper-
iment and at termination. Luminal contents were collected from the caecum after euthanasia. Samples were 
snap-frozen in liquid nitrogen and stored at −80 °C for later analysis. DNA isolation was performed using the 
PowerLyzer PowerSoil Kit (MO BIO Laboratories, Carlsbad, CA USA) using 0.25 g faeces or luminal content 
according to the manufacturer’s protocol. Approximate yield (ng/ml) was first determined by spectrophotometry 
using the NanoDrop 2000 (Thermo Fisher Scientific, Waltham, MA, USA); samples with DNA concentrations 
>10 ng/ml were selected for subsequent analyses.
Targeted sequencing of the 16S rRNA gene was performed at Microsynth (Balgach, Switzerland). The V4 
region was amplified with primers described by Caporaso et al.55 and barcoded in a twostep PCR approach. 
Paired-end sequencing was performed on an Illumina MiSeq system. Pre-filtered paired reads were demulti-
plexed and stitched following mothur’s MiSeq SOP (http://www.mothur.org/wiki/MiSeq_SOP, accessed May 
201556,57) and filtered for length and putative chimeric PCR products (UCHIME58). Reads were taxonomically 
classified and mapped to reference Operational Taxonomic Units (OTUs) at different levels of sequence similarity 
using MAPseq59 against an average linkage pre-clustered reference database of full length 16S rDNA sequences. 
Unmapped sequences were aligned to a bacterial reference 16S model as provided in the package ssu-align (http://
selab.janelia.org/software/ssu-align/ ref.60) using the structure-aware aligner Infernal61. After removing sequences 
which did not align to the model or were not classified as bacterial by MAPseq, reads were pre-clustered (one mis-
match abundance-sorted single linkage) and then hierarchically clustered into OTUs using hpc-clust62 according 
to the average linkage algorithm which has previously been shown to provide reproducible and consistent clus-
tering63. OTU sets were generated at different levels of sequence similarity; in this manuscript, data are shown for 
OTUs at 98% sequence similarity. Further biological analyses were performed using R scripts, particularly relying 
on the R packages vegan27, phyloseq64 and edgeR65. Raw sequence data has been deposited in the NCBI Sequence 
Read Archive (BioProject ID PRJNA309382, http://www.ncbi.nlm.nih.gov/bioproject/PRJNA309382). Analysis 
scripts are available via http://github.com/defleury/2016_Leonardi_et_al_rabbit_tso. Data can be accessed at 
http://meringlab.org/suppdata/2016-rabbit_tso/.
Trichuris suis detection by PCR. Tissue samples (colon, ileum, caecum, brain, kidney, spleen) were col-
lected after euthanasia and immediately snap-frozen in N2. Samples were sent to IBR Inc (Matzingen, Switzerland) 
for detection by PCR. Primers for the ITS2 gene were used (Supplementary Table 4). Primers are based on the 
T.suis specific internal transcribed spacers (ITS)1-5.8S-ITS2 segment of the ribosomal DNA66. The ITS2 copy 
number is proportional to the number of T. suis larvae.
Analysis of peroxidase activity. Peroxidase activity in caecal lysates was measured as previously 
described25. To achieve specificity for neutrophil derived MPO, the assay was conducted in presence of the EPO 
inhibitor aminotriazole (3-Amino-1H-1,2,4-triazole, 95%; Brunschwig, Basel, Switzerland) at pH 6.067. MPO 
activity (indicated as arbitrary units U/g.s) was calculated as mean absorbance (460 nm) per incubation time per 
protein content of the sample in grams determined by BCA assay (ThermoFisher, Rockford, USA).
Faecal flotation. 5 g of fresh faeces were collected 1 day before and 1 day after each TSO-gavage and 9 days 
after start of the DSS-treatment. The samples were suspended immediately in 300 ml water, filtered through a 
1 mm sieve and incubated at RT for 30 min. The supernatant was discarded and 1 ml of the sediment was resus-
pended in 10 ml Sheather’s solution (454 g Sucrose in 355 ml water with 6 ml 37% formalin), mixed briefly and 
centrifuged 5 min at 500 g. 4 drops were collected with a smear loop, transferred to a slide and examined at 10x 
lens objective, (changing the plane of focus during the examination). As a positive control, 1 ml of the TSO-gavage 
solution was suspended in 10 ml Sheather’s solution and analysed as described above.
Statistical analysis. The data obtained from this study were analysed using GraphPad Prism (version 5.04) 
and the R statistical framework (version 3.1.2). If not otherwise indicated, Mann - Whitney U-test for two inde-
pendent samples was used for the comparison of the treatment groups, data are shown as mean ± SEM.
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